Aberrant SHM is thought to be a tumor-specific pathogenetic process targeting proto-oncogenes such as PIM-1, PAX-5, C-MYC, and RhoH/TTF and has been reported in lymphoma to be independent of the immune and EBV status of the host [22, 77] (Table 1). The gene discussed is RHOH; the disease is neoplasm.